Latest market price
22.58
-0.86-3.67%
AORTQT31Artivion, Inc.·NYSE
22.58-3.67%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)-0.07Insider Own6.68%Shs Outstand48.76MPerf Week-3.09%
Market Cap1.10BForward P/E78.20EPS next Y0.29Insider Trans-4.17%Shs Float46.16MPerf Month2.96%
Enterprise Value1.43BPEG—EPS next Q-0.06Short Float8.09%Perf Quarter-17.80%
Income-4.00MP/S2.34EPS this Y-226.17%Short Ratio5.85Perf Half Y-37.64%
Sales471.00MP/B2.47EPS next Y—ROA-0.30%Short Interest3.74MPerf YTD-50.49%
Book/sh9.15P/C14.30EPS next 5Y—ROE-0.71%52W High48.25 -53.20%Perf Year-49.81%
Cash/sh1.58P/FCF—EPS past 3/5Y—ROIC-2.75%52W Low19.16 17.85%Perf 3Y80.35%
Dividend Est.—EV/EBITDA27.96Sales past 3/5Y11.99% 11.75%Gross Margin62.80%Volatility3.94% 4.32%Perf 5Y7.32%
Dividend TTM—EV/Sales3.03EPS Y/Y TTM—Oper. Margin4.00%ATR (14)1.01Perf 10Y32.05%
Dividend Ex-DateDec 09, 2015Quick Ratio2.51Sales Y/Y TTM16.30%Profit Margin-0.67%RSI (14)46.58Recom2.17
Dividend Gr. 3/5Y33.89% —Current Ratio3.47EPS Q/Q—SMA200.97%Beta1.31Target Price38.67
Payout0.00%Debt/Eq0.90Sales Q/Q11.50%SMA50-5.39%Rel Volume1.01Prev Close23.44
Employees1,800LT Debt/Eq0.90EarningsNov 05SMA200-23.17%Avg Volume621.70KPrice22.58
IPO DateFeb 12, 1993Option/ShortYes / YesEPS/Sales Surpr.-11300.00% 4.80%Net Debt/EBITDA6.37Volume627,382Change-3.67%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-20-26ReiteratedJefferies$31
Aug-18-26ReiteratedCanaccord GenuityBuy$39 → $40
Aug-07-26ReiteratedCanaccord GenuityBuy$36 → $39
Jun-16-26ReiteratedCanaccord GenuityBuy$51 → $36
Jun-01-26ReiteratedStifel Nicolaus$55 → $45
Apr-10-26UpgradeLadenburg ThalmannNeutral → Buy
Mar-05-26ReiteratedStifel Nicolaus$55
Dec-17-25ReiteratedCanaccord GenuityBuy$51
Nov-07-25ReiteratedOppenheimerOutperform$30 → $50
Aug-13-25DowngradeLadenburg ThalmannBuy → Neutral
Latest News· Times ET
Oct-28-26
Oct-22-26
Oct-20-26
Oct-12-26
Oct-05-26
Sep-25-26
Sep-23-26
Sep-15-26
Sep-08-26
Sep-04-26
Aug-18-26
Aug-09-26
Aug-07-26
Aug-07-2606:05PM
Aug-06-26
Company

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue471441389354—————
Cost of Goods Sold Incl. D&A175171140125—————
Gross Profit297270249229—————
Selling, General and Administrative Excl. Other243213192209—————
Research and Development35312829—————
Other Operating Expense-10-10-15—————
Operating Income1927396—————
Interest Expense24273425—————
Unusual Expense
—————————
Non-Operating Income (Expense)815-12-2—————
Net Income Before Taxes215-8-22—————
Income Taxes6569—————
Consolidated Net Income-410-13-31—————
Net Income From Continuing Operations-410-13-31—————
Net Income-410-13-31—————
EPS (Recurring)-0.060.22-0.32-0.75—————
EPS (Basic, Before Extraordinaries)-0.060.22-0.32-0.75—————
EPS (Diluted)-0.070.21-0.32-0.75—————
EBITDA51645127—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—217.19———————
Price To Sales Ratio2.354.653.092.07—————
Gross Margin63.0661.2264.0164.69—————
Operating Margin4.036.1210.031.69—————
Net Margin-0.852.27-3.34-8.76—————
Shares Outstanding49454241—————
Market Capitalization1,1062,0521,201733—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$51.76$42.81$33.87$24.92$15.97● Close Price0.00M2.17M4.33M6.50M8.67MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GREEN ANDREW MSVP, Regulatory and QualitySep 10 '26Sale24.9711,480286,65640,160Sep 11
GREEN ANDREW MSVP, Regulatory and QualitySep 03 '26Sale26.021,49338,84251,640Sep 04
GREEN ANDREW MSVP, Regulatory and QualitySep 02 '26Sale27.276,510177,49553,133Sep 04
Mackin James PPresident & CEOAug 19 '26Sale28.9570,0002,026,850877,275Aug 20
GREEN ANDREW MSVP, Regulatory and QualityAug 14 '26Sale28.5561617,58659,643Aug 17
Berry Lance AEVP, COO, CFO & TreasurerAug 14 '26Sale28.5571520,413210,112Aug 17
Holloway Jean FSVP, General CounselAug 12 '26Sale28.4997727,835184,118Aug 12
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Sale20.7044,001910,73960,259Jun 15
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Option Exercise13.3944,001589,07890,259Jun 15
Holloway Jean FSVP, General CounselMar 04 '26Sale38.008,962340,556185,095Mar 04
Horton AmyVP, Chief Accounting OfficerMar 03 '26Sale37.7890134,036139,088Mar 04
Holloway Jean FSVP, General CounselMar 03 '26Sale37.783,843145,172194,057Mar 04
Stanton Marshall S.SVP, Clinical & MD AffairMar 03 '26Sale37.782,14981,18060,097Mar 04
Davis John EChief Commercial OfficerMar 03 '26Sale37.784,573172,748230,794Mar 04
Berry Lance AEVP, COO, CFO & TreasurerMar 03 '26Sale37.786,316238,591210,827Mar 04
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.